

DISCOVER WHAT MIGHT BE POSSIBLE FOR ADVANCED OR RECURRENT OVARIAN CANCER WITH LYNPARZA



Not a real patient.

WHAT IS LYNPARZA?

LYNPARZA is a prescription medicine used to treat adults who have:

- ovarian, fallopian tube, or primary peritoneal cancer:
 - that is advanced and has a certain type of inherited (germline) or acquired (somatic) abnormal *BRCA* gene. LYNPARZA is used as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy
 - in combination with another anti-cancer medicine called bevacizumab when your cancer is advanced and homologous recombination deficiency (HRD)-positive, which is identified by a certain type of abnormal *BRCA* gene or a positive laboratory tumor test for genomic instability. LYNPARZA is used as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy
 - that has come back and has a certain type of inherited or acquired abnormal *BRCA* gene. LYNPARZA is used as maintenance treatment after the cancer has responded to treatment with platinum-based chemotherapy

Your healthcare provider will perform a test to make sure that LYNPARZA is right for you.

It is not known if LYNPARZA is safe and effective in children.

SELECT SAFETY INFORMATION

LYNPARZA has serious risks that may lead to death. These include bone marrow problems called myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), lung problems (pneumonitis), blood clots (venous thromboembolism [VTE]) and liver problems, including drug-induced liver injury (DILI). Signs or symptoms of MDS/AML may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, or bruising or bleeding more easily. Signs or symptoms of pneumonitis may include new or worsening lung problems, including shortness of breath, fever, cough or wheezing. Signs or symptoms of VTE may include pain or swelling in an extremity, shortness of breath, chest pain, breathing that is more rapid than normal, or heart beats faster than normal. Signs or symptoms of DILI may include discomfort on the right side of the stomach-area, dark or "tea-colored" urine, or yellowing of the skin or whites of the eyes. Tell your doctor right away if you have any of these signs or symptoms.

This is a summary of some of the most important information you should know about LYNPARZA. For more information about these and other side effects, as well as other information about treatment with LYNPARZA, please see Important Safety Information throughout and see complete Prescribing Information, including Medication Guide.

Lynparza[®]
olaparib
tablets 150 mg

TABLE OF CONTENTS

Topic	Page
Introduction	3
Maintenance therapy	4
Treatment plan	5
LYNPARZA + bevacizumab for advanced ovarian cancer	6
LYNPARZA alone for advanced ovarian cancer	8
LYNPARZA alone for recurrent ovarian cancer	10
The importance of testing	12
Serious side effects	14
How to take LYNPARZA	16
Common side effects	18
Working with your doctor	19
Patient support	20
Helpful terms and phrases	22

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about LYNPARZA?

LYNPARZA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death.

Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.

Serious side effects continue on page 3.

These are not all the side effects. Please see Important Safety Information throughout and read the complete Prescribing Information, including Medication Guide.



If you are unfamiliar with some of the language used in the brochure, please refer to pages 22 and 23 for key terms and definitions.

Lynparza[®]
olaparib
tablets 150 mg

I INTRODUCING LYNPARZA

Talk to your doctor as early as possible to help prevent your advanced or recurrent ovarian cancer from growing or returning. LYNPARZA can be used as a maintenance therapy after your advanced or recurrent ovarian cancer has responded to platinum-based chemotherapy.

This brochure may help you understand what to expect from treatment, guide your discussion with your doctor, and **give you the confidence that you're exploring all your options to treat your advanced or recurrent ovarian cancer.**

It's important to work closely with your doctor to understand how LYNPARZA fits into your treatment plan.



Not a real patient
or caregiver.

IMPORTANT SAFETY INFORMATION – continued

LYNPARZA may cause serious side effects, including (continued):

Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) (continued).

Your healthcare provider will do blood tests to check your blood cell counts:

- before treatment with LYNPARZA
- every month during treatment with LYNPARZA
- weekly if you have low blood cell counts that last a long time

Serious side effects continue on page 4.

These are not all the side effects. Please see Important Safety Information throughout and read the complete Prescribing Information, including Medication Guide.



Lynparza®
olaparib
tablets 150 mg

MAINTENANCE THERAPY MAY MAKE A DIFFERENCE

There may be more you can do to maintain the results of your prior treatment.

Maintenance therapy is a treatment doctors can use after cancer has responded to chemotherapy. It may help extend the time without cancer growing or returning.

Without maintenance therapy, **advanced ovarian cancer may return in about 70% of women within 3 years** after their first-line treatment, even in those who have no evidence of disease (NED).

~70%
of women
may have
recurrence



ASK YOUR DOCTOR ABOUT MAINTENANCE THERAPY.

IMPORTANT SAFETY INFORMATION – continued

LYNPARZA may cause serious side effects, including (continued):

Lung problems (pneumonitis).

LYNPARZA can cause serious lung problems that can lead to death. Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms.

Serious side effects continue on page 5.

These are not all the side effects. Please see Important Safety Information throughout and read the complete Prescribing Information, including Medication Guide.



Lynparza[®]
olaparib
tablets 150 mg

MAINTENANCE THERAPY MAY BE AN IMPORTANT PART OF YOUR TREATMENT PLAN

Working with your doctor, you can decide on a personalized treatment plan for your unique cancer needs. You'll most likely discuss the following steps, including maintenance therapy, which may help prevent your ovarian cancer from growing or returning.

CONSIDERATIONS FOR YOUR TREATMENT PLAN

✓ TESTING

Tests are used to confirm diagnoses and help create a treatment plan.

Your doctor may test for **BRCA mutations and HRD, which are important biomarkers in ovarian cancer** and may help determine what therapies may work for you.

HRD=homologous recombination deficiency.

✓ CHEMOTHERAPY

Chemotherapy may be prescribed before or after surgery. It can be used on its own or in combination with other therapies.

✓ SURGERY

Your doctor will discuss your surgical options and whether surgery is right for you.

✓ MAINTENANCE THERAPY

Maintenance therapy may help preserve the progress you achieved with chemotherapy.

Your doctor may recommend maintenance therapy using certain treatments in combination or on their own.

IMPORTANT SAFETY INFORMATION – continued

LYNPARZA may cause serious side effects, including (continued):

Blood clots (venous thromboembolism [VTE]). Some people may develop a blood clot in a deep vein, usually in the leg (venous thrombosis) or a clot in the lungs (pulmonary embolism [PE]), which may be severe or lead to death. Tell your healthcare provider right away if you have any symptoms such as pain or swelling in an extremity, shortness of breath, chest pain, breathing that is more rapid than normal (tachypnea), or heart beats faster than normal (tachycardia). Your healthcare provider will monitor you for these symptoms and may prescribe blood thinner medicine.

Serious side effects continue on page 6.

These are not all the side effects. Please see Important Safety Information throughout and read the complete Prescribing Information, including Medication Guide.



Lynparza®
olaparib
tablets 150 mg

LYNPARZA + BEVACIZUMAB FOR ADVANCED OVARIAN CANCER

IS LYNPARZA COMBINATION THERAPY RIGHT FOR YOU?

Your doctor may decide that you are eligible for LYNPARZA + bevacizumab as a first-line maintenance therapy, if your advanced ovarian cancer:

- ✓ Tested positive for HRD (homologous recombination deficiency)
- ✓ Has responded to your first treatment with platinum-based chemotherapy

Your healthcare provider will perform a test to make sure that LYNPARZA is right for you.



Not a real patient
or caregiver.

IMPORTANT SAFETY INFORMATION – continued

LYNPARZA may cause serious side effects, including (continued):

Liver problems, including Drug-Induced Liver Injury (DILI): People taking LYNPARZA may develop liver problems which may be severe and can lead to death. Your healthcare provider should do blood tests before and during your treatment with LYNPARZA. Tell your healthcare provider right away if you notice discomfort on the right side of your stomach-area (abdominal), dark or "tea-colored" urine, or yellowing of your skin or the whites of your eyes (jaundice).

Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LYNPARZA if you get certain side effects.

These are not all the side effects. Please see Important Safety Information throughout and read the complete Prescribing Information, including Medication Guide.



Lynparza[®]
olaparib
tablets 150 mg

CLINICAL TRIAL RESULTS

LYNPARZA + bevacizumab may give adults more time without their HRD-positive advanced ovarian cancer growing or returning compared to bevacizumab.*

A clinical study evaluated patients with advanced ovarian cancer who received LYNPARZA + bevacizumab after responding to platinum-based chemotherapy and bevacizumab. **The results below are from a subset of a study and should be discussed with your doctor.** In the subset of 387 patients with HRD-positive advanced ovarian cancer, 255 patients received LYNPARZA + bevacizumab and 132 patients received bevacizumab + placebo.

67%
↓

LYNPARZA + bevacizumab lowered the risk of disease progression or death by 67% compared to bevacizumab + placebo.[†]

168 out of 255 patients on LYNPARZA + bevacizumab did not see their cancer grow or return compared with 40 out of 132 patients on bevacizumab + placebo.

Adults receiving LYNPARZA + bevacizumab were alive and did not see their HRD-positive advanced ovarian cancer grow or return for a median of over 3 years (37.2 months) compared with 17.7 months for adults on bevacizumab + placebo.

*LYNPARZA + bevacizumab was studied against bevacizumab + placebo.

[†]Based on the design of this study, the statistical meaning of these results may be limited. Talk to your doctor to see if LYNPARZA + bevacizumab is right for you.

IMPORTANT SAFETY INFORMATION – continued

Before taking LYNPARZA, tell your healthcare provider about all of your medical conditions, including if you:

- have lung or breathing problems
- have kidney problems
- are pregnant, become pregnant, or plan to become pregnant. LYNPARZA can harm your unborn baby and may cause loss of pregnancy (miscarriage)

Females who are able to become pregnant:

- your healthcare provider may do a pregnancy test before you start treatment with LYNPARZA

Continues on the next page.

Please see Important Safety Information throughout and read the complete Prescribing Information, including Medication Guide.



Lynparza[®]
olaparib
tablets 150 mg

LYNPARZA ALONE FOR ADVANCED OVARIAN CANCER

IS LYNPARZA ALONE RIGHT FOR YOU?

Your doctor may decide that you are eligible for LYNPARZA taken alone as a first-line maintenance therapy, if your advanced ovarian cancer:

- ✓ Has tested positive for a *BRCA* mutation
- ✓ Has responded to your first treatment with platinum-based chemotherapy

Your healthcare provider will perform a test to make sure that LYNPARZA is right for you.



Not a real patient.

IMPORTANT SAFETY INFORMATION – continued

Before taking LYNPARZA, tell your healthcare provider about all of your medical conditions, including if you (continued):

Females who are able to become pregnant (continued):

- you should use effective birth control (contraception) during treatment with LYNPARZA and for 6 months after the last dose of LYNPARZA. Talk to your healthcare provider about birth control methods that may be right for you
- tell your healthcare provider right away if you become pregnant or think you might be pregnant following treatment with LYNPARZA

Continues on the next page.

Please see Important Safety Information throughout and read the complete Prescribing Information, including Medication Guide.



Lynparza[®]
olaparib
tablets 150 mg

CLINICAL TRIAL RESULTS

LYNPARZA could give adults with a *BRCA* mutation more time progression free after responding to platinum-based chemotherapy.

A clinical study included 391 patients with a *BRCA* mutation and advanced ovarian cancer after they responded to first-line platinum-based chemotherapy. 260 patients took LYNPARZA and 131 took placebo.

70%
↓

LYNPARZA lowered the risk of disease progression or death by 70% compared to placebo.

61% of patients (158 out of 260) taking LYNPARZA were alive and did not see their cancer grow or return at a median follow-up of 3.4 years (41 months) compared with 27% of patients (35 out of 131) on placebo.

**TALK TO YOUR DOCTOR ABOUT A *BRCA* TEST TO
FIND OUT IF YOU'RE ELIGIBLE FOR LYNPARZA.**

IMPORTANT SAFETY INFORMATION – continued

Before taking LYNPARZA, tell your healthcare provider about all of your medical conditions, including if you (continued):

- are breastfeeding or plan to breastfeed. It is not known if LYNPARZA passes into your breast milk. Do not breastfeed during treatment with LYNPARZA and for 1 month after receiving the last dose of LYNPARZA. Talk to your healthcare provider about the best way to feed your baby during this time

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking LYNPARZA and certain other medicines may affect how LYNPARZA works and may cause side effects.

Please see Important Safety Information throughout and read the complete Prescribing Information, including Medication Guide.



[MENU](#)

Lynparza®
olaparib
tablets 150 mg

LYNPARZA ALONE FOR RECURRENT OVARIAN CANCER

IS LYNPARZA ALONE RIGHT FOR YOU?

Your doctor may decide that you are eligible for LYNPARZA as a maintenance therapy if your ovarian cancer:

- ✓ Has come back (also known as recurrent ovarian cancer)
- ✓ Has responded to the most recent treatment with platinum-based chemotherapy
- ✓ Has tested positive for a *BRCA* mutation

Your healthcare provider will perform a test to make sure that LYNPARZA is right for you.

IMPORTANT SAFETY INFORMATION – continued

How should I take LYNPARZA?

- Take LYNPARZA tablets exactly as your healthcare provider tells you
- Your healthcare provider will decide how long you stay on treatment
- Do not change your dose or stop taking LYNPARZA unless your healthcare provider tells you to
- Take LYNPARZA by mouth 2 times a day with or without food
- Each dose should be taken about 12 hours apart
- Swallow LYNPARZA tablets whole. Do not chew, crush, dissolve, or divide the tablets

Continues on next page.

Please see Important Safety Information throughout and read the complete Prescribing Information, including Medication Guide.



Lynparza[®]
olaparib
tablets 150 mg

Not a real patient or a
healthcare professional.

CLINICAL TRIAL RESULTS

LYNPARZA could give adults with a *BRCA* mutation more time progression free

A clinical study included 295 patients with an inherited *BRCA* mutation and ovarian cancer that had returned and responded to platinum-based chemotherapy. 196 patients took LYNPARZA and 99 patients took placebo.

70%
↓

LYNPARZA lowered the risk of disease progression or death by 70% compared with placebo.

89 out of 196 patients on LYNPARZA were alive and did not see their cancer grow or return for a median of more than 1.5 years (19.1 months), compared with 19 out of 99 patients on placebo who did not see their cancer grow or return for a median of 5.5 months.

**TALK TO YOUR DOCTOR ABOUT A *BRCA* TEST TO
FIND OUT IF YOU'RE ELIGIBLE FOR LYNPARZA.**

IMPORTANT SAFETY INFORMATION – continued

**How should I take LYNPARZA?
(continued)**

- If you miss a dose of LYNPARZA, take your next dose at your usual scheduled time. Do not take an extra dose to make up for a missed dose
- If you take too much LYNPARZA, call your healthcare provider or go to the nearest hospital emergency room right away

What should I avoid while taking LYNPARZA?

Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.

Please see Important Safety Information throughout and read the complete Prescribing Information, including Medication Guide.



MENU

Lynparza[®]
olaparib
tablets 150 mg

Know the importance of testing

FOR HRD IN ADVANCED OVARIAN CANCER

Homologous recombination deficiency, or HRD, is an important biomarker of advanced ovarian cancer. An HRD test is a type of genomic test that assesses the DNA profile of your tumor, including different mutations, such as mutations in the *BRCA1* or *BRCA2* genes, and other changes to your DNA.

HRD MIGHT BE MORE COMMON THAN YOU THINK

~50% of women with advanced ovarian cancer test positive for HRD.

Approximately half of these are *BRCA* mutations, so even if you are *BRCA*-negative you could still be HRD-positive.

Knowing your HRD status as early as possible after diagnosis can help to determine whether LYNPARZA + bevacizumab may be a first-line maintenance therapy option for you.



TALK TO
YOUR
DOCTOR
ABOUT AN
HRD TEST

IMPORTANT SAFETY INFORMATION – continued

LYNPARZA may cause serious side effects (see “What is the most important information I should know about LYNPARZA?”).

Nausea or vomiting is common during treatment with LYNPARZA. Tell your healthcare provider if you get nausea or vomiting. Your healthcare provider may prescribe medicines to treat these symptoms.

The most common side effects of LYNPARZA when used alone are:

- tiredness or weakness
- low red blood cell counts
- diarrhea
- loss of appetite

Common side effects continue on next page.

These are not all the side effects. Please see Important Safety Information throughout and read the complete Prescribing Information, including Medication Guide.



Lynparza[®]
olaparib
tablets 150 mg

Know the importance of testing

FOR *BRCA* MUTATIONS IN ADVANCED OR RECURRENT OVARIAN CANCER

A *BRCA* mutation is a change or alteration found in the *BRCA1* or *BRCA2* gene. A *BRCA* mutation can either be acquired or inherited.

There are 2 types of mutations:



Acquired, also known as somatic:

- Develops at some point during a person's life



Inherited, also known as germline:

- Passed down from a parent

Your doctor can perform a *BRCA* test to help determine eligibility for maintenance therapy with LYNPARZA.

IMPORTANT SAFETY INFORMATION – continued

The most common side effects of LYNPARZA when used alone are (continued):

- headache
- changes in the way food tastes
- cough
- low white blood cell counts
- shortness of breath
- dizziness
- indigestion or heartburn
- low platelet counts

The most common side effects of LYNPARZA when used in combination with bevacizumab are:

- tiredness or weakness
- low red blood cell counts

Common side effects continue on page 19.

These are not all the side effects. Please see Important Safety Information throughout and read the complete Prescribing Information, including Medication Guide.



Lynparza[®]
olaparib
tablets 150 mg

I SERIOUS SIDE EFFECTS

It's normal to be concerned about side effects. **Talk to your healthcare provider** immediately if you experience any of these symptoms while taking LYNPARZA.

LYNPARZA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death.

Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include:

- Weakness
- Weight loss
- Fever
- Frequent infections
- Blood in urine or stool
- Shortness of breath
- Feeling very tired
- Bruising or bleeding more easily

Serious side effects continue on the next page.



Your healthcare provider will do blood tests to check your blood cell counts:

- Before treatment with LYNPARZA
- Every month during treatment with LYNPARZA
- Weekly if you have low blood cell counts that last a long time

These are not all the side effects. Please see Important Safety Information throughout and read the complete [Prescribing Information](#), including [Medication Guide](#).



Lynparza[®]
olaparib
tablets 150 mg

| SERIOUS SIDE EFFECTS (continued)



Lung problems (pneumonitis)

LYNPARZA can cause serious lung problems that can lead to death. Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms.

Blood clots (venous thromboembolism [VTE])

Some people may develop a blood clot in a deep vein, usually in the leg (venous thrombosis) or a clot in the lungs (pulmonary embolism [PE]), which may be severe or lead to death. Tell your healthcare provider right away if you have any symptoms such as pain or swelling in an extremity, shortness of breath, chest pain, breathing that is more rapid than normal (tachypnea), or heart beats faster than normal (tachycardia). Your healthcare provider will monitor you for these symptoms and may prescribe blood thinner medicine.

Liver problems, including Drug-Induced Liver Injury (DILI)

People taking LYNPARZA may develop liver problems which may be severe and can lead to death. Your healthcare provider should do blood tests before and during your treatment with LYNPARZA. Tell your healthcare provider right away if you notice discomfort on the right side of your stomach-area (abdominal), dark or "tea-colored" urine, or yellowing of your skin or the whites of your eyes (jaundice).

Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LYNPARZA if you get certain side effects.



YOU CAN REPORT SIDE EFFECTS

These are not all of the possible side effects of LYNPARZA. Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at **1-800-FDA-1088**.

These are not all the side effects. Please see Important Safety Information throughout and read the complete Prescribing Information, including Medication Guide.



I HOW TO TAKE LYNPARZA

LYNPARZA

Take LYNPARZA exactly as your doctor tells you. Two tablets (150 mg each), twice a day, totaling 4 tablets each day by mouth (600 mg daily dose).



**2 TABLETS
IN THE MORNING**
(300 mg)



**2 TABLETS
IN THE EVENING**
(300 mg)

Take doses 12 hours apart, with or without food. Your doctor will determine how long you receive LYNPARZA as maintenance therapy.

Images do not represent the actual size of the tablets.

LYNPARZA + bevacizumab

If bevacizumab is used in combination with LYNPARZA, your doctor will give you an infusion of bevacizumab (15 mg/kg) every 3 weeks. Bevacizumab is a targeted therapy, not chemotherapy.



**2 TABLETS
IN THE MORNING**
(300 mg)



**2 TABLETS
IN THE EVENING**
(300 mg)



**BEVACIZUMAB
EVERY 3 WEEKS**
(15 mg/kg)

Take doses 12 hours apart, with or without food.

Images do not represent the actual size of the tablets.

Your doctor will determine how long you receive LYNPARZA + bevacizumab as maintenance therapy.

How to take LYNPARZA continues on the next page.

Please see Important Safety Information throughout and read the complete [Prescribing Information](#), including [Medication Guide](#).



Lynparza[®]
olaparib
tablets 150 mg

I HOW TO TAKE LYNPARZA (continued)

- **Take LYNPARZA tablets** exactly as your healthcare provider tells you
- Your healthcare provider will decide how long you stay on treatment
- **Do not change your dose or stop taking LYNPARZA** unless your healthcare provider tells you to
- Take LYNPARZA by mouth **2 times a day with or without food**
- Each dose should be taken about **12 hours apart**
- **Swallow LYNPARZA tablets whole.** Do not chew, crush, dissolve, or divide the tablets
- If you miss a dose of LYNPARZA, take your next dose at your usual scheduled time. **Do not take an extra dose** to make up for a missed dose
- If you take too much LYNPARZA, call your healthcare provider or go to the nearest hospital emergency room right away

What should I avoid while taking LYNPARZA?

Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.

Please see Important Safety Information throughout and read the complete [Prescribing Information](#), including [Medication Guide](#).



I COMMON SIDE EFFECTS

Nausea or vomiting is common during treatment with LYNPARZA. Tell your healthcare provider if you get nausea or vomiting. Your healthcare provider may prescribe medicines to treat these symptoms.

The most common side effects of LYNPARZA when used alone are:

- tiredness or weakness
- low red blood cell counts
- diarrhea
- loss of appetite
- headache
- changes in the way food tastes
- cough
- low white blood cell counts
- shortness of breath
- dizziness
- indigestion or heartburn
- low platelet counts

The most common side effects of LYNPARZA when used in combination with bevacizumab are:

- tiredness or weakness
- low red blood cell counts
- diarrhea
- low white blood cell counts
- urinary tract infection
- headache

These are not all of the possible side effects of LYNPARZA.
Call your healthcare provider for medical advice about side effects.
You may [report side effects related to AstraZeneca products](#)
(Opens new window).



Please see Important Safety Information throughout and read the complete [Prescribing Information](#), including [Medication Guide](#).



Lynparza[®]
olaparib
tablets 150 mg

WORKING WITH YOUR DOCTOR WHILE TAKING LYNPARZA



Ask your doctor what to expect

Talk to your doctor about what to expect when taking LYNPARZA. It may help to have a better idea of what you might experience as you start treatment with LYNPARZA.



Write notes about how you're feeling

Sharing this information with your doctor can help them decide on ways to help manage side effects you may be experiencing.



Keep an open dialogue with your doctor

Keep your doctor informed of how you feel, if you're going on a trip, or any other important changes that are happening in your life. You should always talk to your doctor about side effects you experience and how to manage them.

IMPORTANT SAFETY INFORMATION – continued

The most common side effects of LYNPARZA when used in combination with bevacizumab are (continued):

- diarrhea
- low white blood cell counts
- urinary tract infection
- headache

These are not all the possible side effects of LYNPARZA. Call your healthcare provider for medical advice about side effects. *You may report side effects related to AstraZeneca products (Opens new window).*

Please see Important Safety Information throughout and read the complete Prescribing Information, including Medication Guide.



MENU

Lynparza[®]
olaparib
tablets 150 mg

PATIENT SUPPORT FROM ASTRAZENECA

While taking LYNPARZA, you have access to programs from AstraZeneca that are part of our commitment to patient support.

PATIENTS MAY PAY
AS LITTLE AS



PER MONTH

AstraZeneca strives to make LYNPARZA affordable by aiming to provide a \$0 co-pay for all eligible patients

Eligible patients with commercial insurance may pay as little as \$0 per month for LYNPARZA. There are no income requirements to participate in the program, however other restrictions may apply. For more information and eligibility requirements, visit [AZPatientSupport.com](https://www.AZPatientSupport.com)



Consider resources for financial support

Helping you access the care you need

The AstraZeneca Access 360™ program* can help you get started with LYNPARZA. To learn more about the Access 360 program, please call **1-844-ASK-A360 (1-844-275-2360)**, Monday through Friday, 8 AM–6 PM ET, or visit www.MyAccess360.com

This description of the Access 360 program is for informational purposes only. Access 360 does not file claims or appeals on behalf of healthcare professionals or patients and makes no representation or guarantee concerning reimbursement or coverage for any service or item.

*Terms and conditions apply. See site for full eligibility and terms of use.



Caring for your loved one—and yourself

Looking after your loved one on LYNPARZA takes time and a lot of energy. Find a resource for caregivers at [LYNPARZA.com](https://www.LYNPARZA.com).

Please see Important Safety Information throughout and read the complete [Prescribing Information](#), including [Medication Guide](#).



| MyLYNPARZA IS WITH YOU ON YOUR JOURNEY

MyLYNPARZA is a support program from AstraZeneca for you during treatment with LYNPARZA. Both you and your caregiver can sign up.



SUPPORT

Receive emails for adults with your specific type of cancer. You'll learn tips on taking care of yourself, ways to help manage side effects, and more.



EDUCATION

You and your caregiver can receive educational materials including tips for caregivers, how you and your doctor can manage side effects, and how to take LYNPARZA.



RESOURCES

Sign up online to receive items such as a treatment journal to write down your thoughts and questions for your doctor.

MyLYNPARZA
SUPPORT PROGRAM

AstraZeneca 

IF YOU HAVEN'T ALREADY JOINED MyLYNPARZA, YOU CAN SIGN UP AT [MyLYNPARZA.COM](https://www.mylpnarza.com).

Please see Important Safety Information throughout and read the complete [Prescribing Information](#), including [Medication Guide](#).



MENU

Lynparza[®]
olaparib 
tablets 150 mg

I HELPFUL TERMS AND PHRASES

BRCA MUTATION

A change or alteration found in the *BRCA1* or *BRCA2* gene. A *BRCA* mutation can be inherited (germline), which means it was passed down from a family member, or acquired (somatic), which means it was not passed down.

COMBINATION THERAPY

Two or more different medicines used at the same time to treat a patient.

FIRST-LINE TREATMENT

This is what is considered the beginning treatment given for a disease. It is often part of a standard set of procedures and treatments, such as surgery, chemotherapy, and radiation.

GENETIC MUTATION

Any change in the DNA sequence of a cell. A mutation may be inherited from a family member or acquired (developed during your lifetime).

GENETIC TESTING

Is used to look for inherited mutations, including inherited *BRCA* mutations. It can help you and your doctor better understand your cancer and how it responds to different therapies.

GENOMIC TESTING

Is used to learn about the genome of your cancer cells and what makes them different from normal cells. A genomic test is a laboratory test that examines the unique DNA of your tumor. This type of test may come from a biopsy that is taken at diagnosis or during surgery. An HRD tumor test is one type of genomic test. It can help you and your doctor better understand your cancer and how it responds to different therapies.

HRD

Having HRD (homologous recombination deficiency) means that your cells have an inability to repair breaks in the structure of your DNA. HRD can be caused by different kinds of mutations, such as mutations in the *BRCA* gene, or other altered forms of gene expression.

TO LEARN MORE ABOUT THE WORDS AND TERMINOLOGY USED IN THIS BROCHURE, TALK TO YOUR DOCTOR.

Please see Important Safety Information throughout and read the complete [Prescribing Information](#), including [Medication Guide](#).



I HELPFUL TERMS AND PHRASES (continued)

MAINTENANCE THERAPY

A treatment used after you have responded to initial therapy. It can help keep cancer from growing or returning. LYNPARZA can be used in certain people as maintenance therapy.

MEDIAN

The middle number in a list of numbers arranged from the lowest to highest.

NED

No evidence of disease (NED) is often used when there is no physical evidence of the disease after treatment.

PARP

Also called poly (ADP-ribose) polymerase. A protein that is involved in many functions in the cell, including repairing DNA damage.

PARP INHIBITOR (PARPi)

LYNPARZA is a PARP inhibitor. It helps kill cancer cells by preventing PARP from repairing their DNA. A PARP inhibitor may also affect healthy cells

PLACEBO

An inactive treatment that looks the same as, and is given the same way as, an active drug or treatment that is being tested.

RECURRENT CANCER

This is cancer that comes back after treatment where no evidence of cancer was detected. The process of coming back is called recurrence.

TO LEARN MORE ABOUT THE WORDS AND TERMINOLOGY USED IN THIS BROCHURE, TALK TO YOUR DOCTOR.

Please see Important Safety Information throughout and read the complete [Prescribing Information](#), including [Medication Guide](#).



Lynparza[®]
olaparib 
tablets 150 mg

MAKE THIS YOUR TIME TO TALK TO YOUR DOCTOR ABOUT LYNPARZA

LYNPARZA is:

- ✓ a maintenance therapy for certain adults with advanced or recurrent ovarian cancer
- ✓ a targeted treatment called a PARP inhibitor
- ✓ an oral medication that is 2 tablets taken twice a day

Talk to your doctor about getting tested to see if LYNPARZA is right for you.

VISIT [LYNPARZA.COM](https://lynparza.com) TO LEARN MORE.

SELECT SAFETY INFORMATION

LYNPARZA has serious risks that may lead to death. These include bone marrow problems called myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), lung problems (pneumonitis), blood clots (venous thromboembolism [VTE]) and liver problems, including drug-induced liver injury (DILI). Signs or symptoms of MDS/AML may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, or bruising or bleeding more easily. Signs or symptoms of pneumonitis may include new or worsening lung problems, including shortness of breath, fever, cough or wheezing. Signs or symptoms of VTE may include pain or swelling in an extremity, shortness of breath, chest pain, breathing that is more rapid than normal, or heart beats faster than normal. Signs or symptoms of DILI may include discomfort on the right side of the stomach-area, dark or "tea-colored" urine, or yellowing of the skin or whites of the eyes. Tell your doctor right away if you have any of these signs or symptoms.

This is a summary of some of the most important information you should know about LYNPARZA. For more information about these and other side effects, as well as other information about treatment with LYNPARZA, please see Important Safety Information throughout and see complete [Prescribing Information](#), including [Medication Guide](#).



LYNPARZA is a registered trademark and AstraZeneca Access 360 is a trademark of the AstraZeneca group of companies. ©2025 AstraZeneca. All rights reserved. US-101802 Last Updated 7/25



**Not a real caregiver
or patient.**



Lynparza[®]
olaparib
tablets 150 mg